Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
about
Targeting angiogenesis in gynecologic cancersLessons learned from the bevacizumab experienceProfile of pazopanib and its potential in the treatment of epithelial ovarian cancerUrinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugsMagnesium, zinc, arsenic, selenium and platinum urinary excretion from cancer patients of Antofagasta region, Chile: multi-metal approachProteins from Avastin® (bevacizumab) show tyrosine nitrations for which the consequences are completely unclearThe Emerging Role of Tyrosine Kinase Inhibitors in Ovarian Cancer Treatment: A Systematic Review.A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesisIntensity-modulated whole abdomen irradiation following adjuvant carboplatin/taxane chemotherapy for FIGO stage III ovarian cancer : four-year outcomes.Ovarian function following targeted anti-angiogenic therapy with bevacizumabRegulation of tumor angiogenesis by EZH2.VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapyCombination therapy of VEGF-trap and gemcitabine results in improved anti-tumor efficacy in a mouse lung cancer modelA phase 1b, open-label study of trebananib plus bevacizumab or motesanib in patients with solid tumours.Inhibition of ovarian cancer by RGD-P125A-endostatin-Fc fusion proteins.Cardiotoxicity of molecularly targeted agentsSARI inhibits angiogenesis and tumour growth of human colon cancer through directly targeting ceruloplasmin.Bevacizumab for the treatment of recurrent ovarian cancer: a retrospective cohort studyBevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.2-methoxyestradiol in the pathophysiology of endometriosis: focus on angiogenesis and therapeutic potential.Bevacizumab combination therapy: a review of its use in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.Bevacizumab: a review of its use in advanced cancer.Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer.The safety and efficacy of bevacizumab in the treatment of patients with recurrent or metastatic cervical cancer.Bevacizumab and its use in epithelial ovarian cancer.Mechanism of anti-angiogenic property of gold nanoparticles: role of nanoparticle size and surface charge.Effects of 4 multitargeted receptor tyrosine kinase inhibitors on regional hemodynamics in conscious, freely moving rats.Angiogenesis inhibitors and symptomatic anal ulcers in metastatic colorectal cancer patients *.
P2860
Q26824766-EA98AE48-4F9B-4E3C-84D1-4F78140A1E01Q26852509-95D0C04D-3FBF-4759-87C8-25BA6E6E82E1Q27011840-30B34979-CA12-4167-AC93-A3B6CBB279F4Q28388226-E10CDA0A-5EB6-4D4E-9653-09F5D32C5FA2Q28391017-7AC01C04-7B54-458B-BA95-2B02499520D5Q28482364-ECE6E795-0506-4278-A8B3-7486CD5CB3C0Q30248645-1EF60300-0ADF-400E-9D0A-A9B0BF02F744Q30540674-1EBEA626-81ED-4E52-8422-D224DC4AA0AFQ33421285-8EE77D5E-12C1-4594-A9A4-93EB5FC47DD4Q33748232-AA207331-1CAD-4CC3-B10A-F99B0A6CE08AQ34073170-F22F2960-AEE6-47E4-82D0-15719642E8CFQ34310069-F8D5C395-CEBE-40F4-9520-86BD8FE69095Q34849516-A70E402C-85FE-4CE2-AAD7-44FF8C8FF6E7Q34956830-A2B4C733-300E-4653-BFBD-CF62B599D038Q35164399-7F952F3C-C904-478F-9D76-F33326F9B1F6Q35878459-82AFAEF1-616A-4CAF-B385-57FD6944B3ACQ37061077-67A64873-3989-4F3D-B004-75CE24CBCB77Q37401623-2E02A0DD-6660-40B3-8C4C-3FA05211A372Q38003707-C94845D9-9B4E-40F3-B7FC-7F90D1088CBEQ38033141-927D83E7-F80D-4C95-99FD-CFA7AF7C139EQ38111265-4BAF9A0E-10E2-4FE2-A433-6842551895B7Q38260176-4ADD8EEA-BB00-4F1D-9704-E3878DD2FB7FQ38757677-A73641A8-AD66-4030-9B19-E21C2F8D6E2CQ38810865-6FF9B225-EF89-4778-9927-F1542E7DB01BQ39782817-D2E16ACB-C93F-469F-9F41-30E32DFB818AQ41828347-B3AA76FC-92A8-480A-ADFF-717352A710F9Q42323403-2DF1A29C-27F8-492C-8E62-386ECEE7DF3AQ47321047-57F929F9-9CE0-47DF-B367-644FE9954DA9
P2860
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
@ast
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
@en
type
label
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
@ast
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
@en
prefLabel
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
@ast
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
@en
P2093
P2860
P1433
P1476
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.
@en
P2093
Anil K Sood
Rebecca L Stone
Robert L Coleman
P2860
P304
P356
10.1016/S1470-2045(09)70362-6
P577
2010-03-10T00:00:00Z